AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21649779 — intervention group
Group type: COMPARATOR
Intervention: Nonsteerable sheath (group NS)
Number of subjects: 80
Study 21649779 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with incomplete MI block
Number of subjects: 80
Study 21649779 — intervention group
Group type: COMPARATOR
Intervention: Patients with achieved MI block
Number of subjects: 80
Study 19674727 — intervention group
Group type: EXPERIMENTAL
Intervention: Staked-on syringe design
Number of subjects: 464
Study 19674727 — intervention group
Group type: EXPERIMENTAL
Intervention: Both syringe designs
Number of subjects: 464
Study 19674727 — intervention group
Group type: COMPARATOR
Intervention: Luer cone syringe design
Number of subjects: 464
Study 19674727 — intervention group
Group type: EXPERIMENTAL
Intervention: Staked-on syringe design (after September 22, 2006)
Number of subjects: 464
Study 19674727 — intervention group
Group type: COMPARATOR
Intervention: Luer cone syringe design (after September 22, 2006)
Number of subjects: 464
Study 16466610 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 150 mg/day
Number of subjects: 370
Study 16466610 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 300 mg/day
Number of subjects: 370
Study 16466610 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 600 mg/day
Number of subjects: 370
Study 16466610 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin (all doses)
Number of subjects: 370
Study 16466610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 370
Study 15165384 — intervention group
Group type: EXPERIMENTAL
Intervention: Whirlpool and infrared GaAs diode laser with a frequency of 100 Hz applied between the 8th and 21st days postoperatively
Number of subjects: 25
Study 15165384 — intervention group
Group type: COMPARATOR
Intervention: Placebo (laser instrument switched off during applications)
Number of subjects: 25
Study 11303491 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-variety (LV) diet
Number of subjects: 12
Study 11303491 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-variety (MV) diet
Number of subjects: 12
Study 11303491 — intervention group
Group type: EXPERIMENTAL
Intervention: High-variety (HV) diet
Number of subjects: 12
Study 9049555 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep halothane anaesthesia (2% end-tidal concentration)
Number of subjects: 100
Study 9049555 — intervention group
Group type: COMPARATOR
Intervention: 1% halothane and suxamethonium anaesthesia
Number of subjects: 100
Study 8325041 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin (1200 mg/day for 15 days)
Number of subjects: 58
Study 8325041 — intervention group
Group type: COMPARATOR
Intervention: Lactulose (30 g/day for 15 days)
Number of subjects: 58
Study 3090597 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.347 g/kg ethanol
Number of subjects: 18
Study 3090597 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.694 g/kg ethanol
Number of subjects: 18
Study 3090597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 29226494 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT) for problem gambling
Number of subjects: 0
Study 29226494 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine CBT treatments
Number of subjects: 0
Study 29226494 — intervention group
Group type: COMPARATOR
Intervention: Exposure therapy for problem gambling
Number of subjects: 0
Study 29226494 — intervention group
Group type: COMPARATOR
Intervention: Patients of a gambling help service
Number of subjects: 0
Study 26847318 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic Exercise (TE)
Number of subjects: 46
Study 26847318 — intervention group
Group type: EXPERIMENTAL
Intervention: Occupation Based Intervention (OBI) + Therapeutic Exercise (TE)
Number of subjects: 46
Study 25703450 — intervention group
Group type: EXPERIMENTAL
Intervention: CGA-based care at the AGU in addition to usual care
Number of subjects: 382
Study 24081236 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein diet
Number of subjects: 742
Study 24081236 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet
Number of subjects: 742
Study 24081236 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 742
Study 24081236 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein/low-GI diet
Number of subjects: 742
Study 24081236 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein/high-GI diet
Number of subjects: 742
Study 24081236 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein/low-GI diet
Number of subjects: 742
Study 24081236 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein/high-GI diet
Number of subjects: 742
Study 20500280 — intervention group
Group type: EXPERIMENTAL
Intervention: Clamped catheter group
Number of subjects: 113
Study 20500280 — intervention group
Group type: COMPARATOR
Intervention: Free drainage group
Number of subjects: 113
Study 17563996 — intervention group
Group type: EXPERIMENTAL
Intervention: Voluven (hydroxyethylstarch 130/0.4)
Number of subjects: 35
Study 17563996 — intervention group
Group type: COMPARATOR
Intervention: Dextrans
Number of subjects: 35
Study 15068184 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ankle-foot orthosis (AAFO) with variable impedance control
Number of subjects: 2
Study 15068184 — intervention group
Group type: COMPARATOR
Intervention: Zero impedance control strategy
Number of subjects: 2
Study 15068184 — intervention group
Group type: COMPARATOR
Intervention: Constant impedance control strategy
Number of subjects: 2
Study 15068184 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable impedance control strategy
Number of subjects: 2
Study 11414348 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for alcohol and drug abuse
Number of subjects: 162
Study 10021955 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 50
Study 10021955 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 50
Study 7826557 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium/high-potassium diet
Number of subjects: 587
Study 7826557 — intervention group
Group type: COMPARATOR
Intervention: Usual diet
Number of subjects: 587
Study 7826557 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium/high-potassium diet with chlorthalidone (25 mg/day)
Number of subjects: 587
Study 7826557 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium/high-potassium diet with atenolol (50 mg/day)
Number of subjects: 587
Study 7826557 — intervention group
Group type: COMPARATOR
Intervention: Usual diet with chlorthalidone (25 mg/day)
Number of subjects: 587
Study 7826557 — intervention group
Group type: COMPARATOR
Intervention: Usual diet with atenolol (50 mg/day)
Number of subjects: 587
Study 3279101 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nutrient infusion containing amino acids (3.4 g/h), dextrose (20 g/h), and insulin (1.6 units/h)
Number of subjects: 12
Study 3279101 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nutrient infusion containing amino acids, glucose, and insulin
Number of subjects: 12
Study 3279101 — intervention group
Group type: COMPARATOR
Intervention: Standard commercial mixture of amino acids
Number of subjects: 12
Study 30901599 — intervention group
Group type: EXPERIMENTAL
Intervention: SNSI‐CHI (Chinese Version of the Student Nurse Stress Index Scale)
Number of subjects: 1100
Study 30901599 — intervention group
Group type: EXPERIMENTAL
Intervention: SNSI‐CHI
Number of subjects: 1100
Study 28812392 — intervention group
Group type: EXPERIMENTAL
Intervention: Performing arts module of the DASH questionnaire
Number of subjects: 130
Study 28812392 — intervention group
Group type: COMPARATOR
Intervention: General DASH questionnaire
Number of subjects: 130
Study 28812392 — intervention group
Group type: COMPARATOR
Intervention: Pain disability index
Number of subjects: 130
Study 28812392 — intervention group
Group type: COMPARATOR
Intervention: Short-Form 36
Number of subjects: 130
Study 28812392 — intervention group
Group type: COMPARATOR
Intervention: Playing-related musculoskeletal disorder (PRMD) intensity
Number of subjects: 130
Study 28812392 — intervention group
Group type: COMPARATOR
Intervention: Pain intensity
Number of subjects: 130
Study 26815247 — intervention group
Group type: EXPERIMENTAL
Intervention: MILD procedure
Number of subjects: 302
Study 26815247 — intervention group
Group type: COMPARATOR
Intervention: Epidural steroid injections (ESIs)
Number of subjects: 302
Study 23404665 — intervention group
Group type: EXPERIMENTAL
Intervention: PROSPER intervention
Number of subjects: 317
Study 23404665 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 317
Study 22891287 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular route of subvirion inactivated influenza A virus subtype H5N1 vaccine (38.7 μg of H5N1 hemagglutinin)
Number of subjects: 227
Study 22891287 — intervention group
Group type: COMPARATOR
Intervention: Intradermal route of subvirion inactivated influenza A virus subtype H5N1 vaccine (38.7 μg of H5N1 hemagglutinin)
Number of subjects: 227
Study 20472059 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic dissolution testing with pH-gradient
Number of subjects: 0
Study 20472059 — intervention group
Group type: COMPARATOR
Intervention: Conventional dissolution testing at pH 1, pH 5.5, or pH 6.8
Number of subjects: 0
Study 17483649 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral risedronate 5 mg/day after the fifth postoperative day
Number of subjects: 46
Study 17483649 — intervention group
Group type: COMPARATOR
Intervention: No drug treatment (Control)
Number of subjects: 46
Study 15926385 — intervention group
Group type: EXPERIMENTAL
Intervention: Chhabra shunt
Number of subjects: 195
Study 15926385 — intervention group
Group type: COMPARATOR
Intervention: Codman shunt
Number of subjects: 195
Study 12070571 — intervention group
Group type: EXPERIMENTAL
Intervention: Magneto-treated blood autotransfusion
Number of subjects: 66
Study 10475183 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily application of a sun protection factor 15-plus sunscreen
Number of subjects: 1621
Study 10475183 — intervention group
Group type: EXPERIMENTAL
Intervention: Betacarotene supplementation (30 mg per day)
Number of subjects: 1621
Study 10475183 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1621
Study 10475183 — intervention group
Group type: COMPARATOR
Intervention: Sunscreen plus placebo tablets
Number of subjects: 1621
Study 10475183 — intervention group
Group type: COMPARATOR
Intervention: Betacarotene only
Number of subjects: 1621
Study 10475183 — intervention group
Group type: COMPARATOR
Intervention: Placebo only
Number of subjects: 1621
Study 8688975 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonspecific hospital mattress
Number of subjects: 20
Study 8688975 — intervention group
Group type: EXPERIMENTAL
Intervention: First foam mattress
Number of subjects: 20
Study 8688975 — intervention group
Group type: EXPERIMENTAL
Intervention: Second foam mattress
Number of subjects: 20
Study 8688975 — intervention group
Group type: EXPERIMENTAL
Intervention: Air mattress
Number of subjects: 20
Study 8688975 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-filled mattress
Number of subjects: 20
Study 8688975 — intervention group
Group type: COMPARATOR
Intervention: Standard mattress
Number of subjects: 20
Study 1681778 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 28
Study 1681778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 7042206 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocol group (median values of survivors as therapeutic goals)
Number of subjects: 100
Study 7042206 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal values of unstressed healthy volunteers as therapeutic goals)
Number of subjects: 100
Study 30406509 — intervention group
Group type: EXPERIMENTAL
Intervention: Propolis 0.5%
Number of subjects: 397
Study 30406509 — intervention group
Group type: COMPARATOR
Intervention: Aciclovir 5%
Number of subjects: 397
Study 28818225 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTitouch (AT) device
Number of subjects: 89
Study 28818225 — intervention group
Group type: COMPARATOR
Intervention: Compression Stockings (CS)
Number of subjects: 89
Study 25830400 — intervention group
Group type: EXPERIMENTAL
Intervention: Implant-supported fixed partial dentures (IFPDs)
Number of subjects: 12
Study 23485949 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐HTR1B G861C genetic variant
Number of subjects: 387
Study 22057411 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture treatment based on identified CM patterns
Number of subjects: 16
Study 22057411 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 16
Study 18723297 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-escalated three-dimensional conformal radiotherapy (3D-CRT) at doses of 66, 72, 78, and 84 Gy with concurrent Carmustine 80 mg/m² during RT and every 8 weeks for 6 cycles
Number of subjects: 209
Study 17526474 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask anesthesia (LMA) with fentanyl plus propofol
Number of subjects: 46
Study 17526474 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anesthesia with bupivacaine
Number of subjects: 46
Study 17526474 — intervention group
Group type: COMPARATOR
Intervention: Control group (LMA)
Number of subjects: 46
Study 17526474 — intervention group
Group type: COMPARATOR
Intervention: Control group (Spinal anesthesia)
Number of subjects: 46
Study 15105283 — intervention group
Group type: EXPERIMENTAL
Intervention: B9340 (bradykinin receptor antagonist)
Number of subjects: 14
Study 11251666 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed prostheses
Number of subjects: 48
Study 11251666 — intervention group
Group type: COMPARATOR
Intervention: Removable overdenture
Number of subjects: 48
Study 9613426 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium-chain triglycerides (MCT) feeding formulas
Number of subjects: 0
Study 9613426 — intervention group
Group type: COMPARATOR
Intervention: Feeding without MCT
Number of subjects: 0
Study 8580272 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg
Number of subjects: 296
Study 8580272 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg
Number of subjects: 296
Study 8580272 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 60 mg
Number of subjects: 296
Study 8580272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 296
Study 2125839 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (imagery)
Number of subjects: 0
Study 2125839 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1 (imagery) and Group 2 (placebo controls) combined
Number of subjects: 0
Study 2125839 — intervention group
Group type: COMPARATOR
Intervention: Group 2 (placebo controls)
Number of subjects: 0
Study 2125839 — intervention group
Group type: COMPARATOR
Intervention: Group 3 (control)
Number of subjects: 0
Study 7220406 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin estolate preparation (500 mg)
Number of subjects: 6
Study 7220406 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin propionate preparation (500 mg)
Number of subjects: 6
Study 7220406 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin stearate preparation (500 mg)
Number of subjects: 6
Study 7220406 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of serum and plasma concentrations
Number of subjects: 6
Study 30171442 — intervention group
Group type: EXPERIMENTAL
Intervention: Photobiomodulation (PBM)
Number of subjects: 26
Study 30171442 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 28547998 — intervention group
Group type: EXPERIMENTAL
Intervention: Omarigliptin 25 mg once weekly
Number of subjects: 201
Study 28547998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 26512041 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 124
Study 26512041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 23065731 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral strategy 1 (any of inflammatory back pain (IBP), HLA‐B27 or sacroiliitis on imaging)
Number of subjects: 1072
Study 23065731 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral strategy 2 (two of the following: IBP, HLA‐B27, sacroiliitis, family history of axial SpA, good response to non‐steroidal anti‐inflammatory drugs, extra‐articular manifestations)
Number of subjects: 1072
Study 23065731 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both strategies
Number of subjects: 1072
Study 21156068 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 week intensive group behavioural support course
Number of subjects: 17
Study 21156068 — intervention group
Group type: COMPARATOR
Intervention: 7 week brief advice only course
Number of subjects: 17
Study 18398081 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 free fatty acids (4 g/d)
Number of subjects: 738
Study 18398081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 738
Study 16618399 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Number of subjects: 113
Study 16618399 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study 12582792 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable calcium phosphate bone cement (Norian SRS)
Number of subjects: 52
Study 12582792 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous pinning and immobilisation in a cast for 6 weeks (Control)
Number of subjects: 52
Study 10879638 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% ofloxacin solution
Number of subjects: 30
Study 10879638 — intervention group
Group type: COMPARATOR
Intervention: Combination of fortified tobramycin (1.5%) and cefazolin (5%) solutions
Number of subjects: 30
Study 8979380 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive stereotypes of aging (subliminal activation)
Number of subjects: 0
Study 8979380 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative stereotypes of aging (subliminal activation)
Number of subjects: 0
Study 8979380 — intervention group
Group type: COMPARATOR
Intervention: Young individuals (control group)
Number of subjects: 0
Study 1633050 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopentol
Number of subjects: 200
Study 1633050 — intervention group
Group type: COMPARATOR
Intervention: Metrizoate
Number of subjects: 200
Study 1633050 — intervention group
Group type: EXPERIMENTAL
Intervention: Both media
Number of subjects: 200
Study 6329004 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 50
Study 6329004 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 31493548 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D model
Number of subjects: 102
Study 31493548 — intervention group
Group type: COMPARATOR
Intervention: Textbook
Number of subjects: 102
Study 30124525 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Positive Airway Pressure (CPAP)
Number of subjects: 0
Study 30124525 — intervention group
Group type: EXPERIMENTAL
Intervention: Good CPAP compliance
Number of subjects: 0
Study 27038225 — intervention group
Group type: EXPERIMENTAL
Intervention: p-synephrine (3 mg kg(-1))
Number of subjects: 18
Study 27038225 — intervention group
Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 18
Study 23281064 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 10
Study 23281064 — intervention group
Group type: COMPARATOR
Intervention: Sham depletion (placebo)
Number of subjects: 10
Study 23281064 — intervention group
Group type: COMPARATOR
Intervention: Comparison of ATD relative to sham condition
Number of subjects: 10
Study 22770575 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide 1% plus timolol 0.5% suspension
Number of subjects: 62
Study 22770575 — intervention group
Group type: COMPARATOR
Intervention: Dorzolamide 2% plus timolol 0.5% solution
Number of subjects: 62
Study 21333194 — intervention group
Group type: EXPERIMENTAL
Intervention: Octyl‐cyanoacrylate tissue adhesive (OCT)
Number of subjects: 40
Study 21333194 — intervention group
Group type: COMPARATOR
Intervention: Standard suture technique (4‐0 monocryl suture)
Number of subjects: 40
Study 17992072 — intervention group
Group type: EXPERIMENTAL
Intervention: Hope intervention
Number of subjects: 40
Study 17261962 — intervention group
Group type: EXPERIMENTAL
Intervention: CPB with Baxter Duraflo II heparin-coated circuits, high doses of aprotinin, and pre-CPB hemofiltration
Number of subjects: 27
Study 17261962 — intervention group
Group type: COMPARATOR
Intervention: Conventional CPB
Number of subjects: 27
Study 15012843 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive impairment group
Number of subjects: 60
Study 15012843 — intervention group
Group type: COMPARATOR
Intervention: Residential facility control
Number of subjects: 60
Study 15012843 — intervention group
Group type: COMPARATOR
Intervention: Community control
Number of subjects: 60
Study 11015085 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroidectomy in patients with 3 degrees HPT
Number of subjects: 96
Study 11015085 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroidectomy in patients with 2 degrees HPT
Number of subjects: 96
Study 11015085 — intervention group
Group type: EXPERIMENTAL
Intervention: Parathyroidectomy in patients with 1 degrees HPT
Number of subjects: 96
Study 11015085 — intervention group
Group type: COMPARATOR
Intervention: Control group (thyroid disease)
Number of subjects: 96
Study 9553234 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA buprenorphine (intravenous)
Number of subjects: 50
Study 9553234 — intervention group
Group type: COMPARATOR
Intervention: PCA morphine
Number of subjects: 50
Study 8094940 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine 50-100 mg + midazolam 1-3 mg
Number of subjects: 0
Study 8094940 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 50-100 micrograms + midazolam 1-3 mg
Number of subjects: 0
Study 8094940 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil 5-10 micrograms + midazolam 1-3 mg
Number of subjects: 0
Study 8094940 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 150-300 micrograms + midazolam 1-3 mg
Number of subjects: 0
Study 8094940 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine 50-100 mg + midazolam 1-3 mg (lower gastrointestinal patients)
Number of subjects: 0